iFLT-PET/CT is an early and superior predictor of progression-free survival after chemotherapy and immunotherapy for diffuse large B-cell lymphoma

¹⁸ F -fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with comprehensive computer tomography (FDG-PET/CT) is used for staging, re-staging and efficacy evaluation at the end of treatment for diffuse large B-cell lymphoma (DLBCL) Mature method
.

Although the predictive ability of FDG-PET/CT for DLBCL has been confirmed in a number of retrospective and prospective studies, the predictive value of iFDG-PET/CT for DLBCL is still controversial

¹⁸ 18 F -fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with comprehensive computed tomography (FDG-PET/CT) is the staging, re-staging and efficacy evaluation at the end of treatment for diffuse large B-cell lymphoma (DLBCL) Mature method

Minamimoto, R et al.

Explore the use of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclic In patients with diffuse large B-cell lymphoma (DLBCL) treated with phosphoramide and doxorubicin (R-EPOCH), whether 3'-deoxy-3'-[ ¹⁸ F]fluorothymidine (iFLT) PET/CT is good Based on ¹⁸ F-fluorodeoxyglucose (iFDG) PET/CT to predict progression-free survival (PFS)
.

Explore the use of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclic In patients with diffuse large B-cell lymphoma (DLBCL) treated with phosphoramide and doxorubicin (R-EPOCH), whether 3'-deoxy-3'-[ ¹⁸ F]fluorothymidine (iFLT) PET/CT is good Based on ¹⁸ F-fluorodeoxyglucose (iFDG) PET/CT to predict progression-free survival (PFS)
.

^{18 18}

3-year and 5-year PFS rate based on IFLT-PET/CT and Deauville standards

3-year and 5-year PFS rate based on IFLT-PET/CT and Deauville standards

Ninety- two DLBCL patients underwent FLT-PET/CT and FDG-PET/CT examinations 18-24 days after two cycles of R-CHOP/R-EPOCH
.

Deauville standard, Percist1.

Ninety- two DLBCL patients underwent FLT-PET/CT and FDG-PET/CT examinations 18-24 days after two cycles of R-CHOP/R-EPOCH

Kaplan-Meier plots of PFS in patients with iFLT-PET/CT negative, iFLT-PET/CT positive, Deauville type negative and positive
.

The PFS of iFLT-PET/CT positive patients was significantly shorter than that of iFLT-PET/CT negative patients (P<.

Kaplan-Meier plots of PFS in patients with iFLT-PET/CT negative, iFLT-PET/CT positive, Deauville type negative and positive

Kaplan-Meier plots of PFS in iFLT-PET/CT negative, iFLT-PET/CT positive, Percist negative and positive patients
.

The PFS of iFLT-PET/CT-positive patients was significantly shorter than that of iFLT-PET/CT-negative patients (P<.

Kaplan-Meier plots of PFS in iFLT-PET/CT negative, iFLT-PET/CT positive, Percist negative and positive patients

According to Deauville criteria, 53 cases (58%) were negative for iFDG-PET/CT and 39 cases (42%) were positive

In DLBCL patients who were given R-CHOP/R-EPOCH treatment, and in DLBCL patients who were given R-CHOP/R-EPOCH treatment, iFLT-PET/CT was superior to iFDG-PET/ CT in both quantitative evaluation and treatment evaluation criteria.

Original source

Minamimoto, R.
, Fayad, L.
, Vose, J.
et al.
¹⁸ F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study.
Eur J Nucl Med Mol Imaging48,2883–2893 (2021).
https://doi.
org/10.
1007/s00259-021-05353-9

Minamimoto, R.
, Fayad, L.
, Vose, J.
et al.
¹⁸ 18 F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study.
Eur J Nucl Imaging MoI Med48,  2883-2893 (2021).
Eur J Nucl Med MoI Imaging 48,  https://doi.
org/10.
1007/s00259-021-05353-9 in this message